Adverum Biotechnologies: Ocular / rare disease gene thx. ADVM-022 in P1 OPTIC study in wAMD. Reported 24-wk data from cohort 1 (6 pts) in September (no rescue injections). 52-week data from cohort 1 and 24-week data from cohort 2 exp. 1H20. Collaborations in place with Regeneron and Editas.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Ophthalmology, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Gene Therapy
Website:
Profiles:
Address:
Menlo Park, California
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.